Gilead Sciences, Inc. (GILD) -Strong Performance across base business

Gilead Sciences, Inc. (GILD) (Q2FY23)

Stock Performance – Gilead Sciences stock price showed a volatile trend in past 3-months. It decreased by 1.59% during the period. The stock price increased by 20.1% in past 1-year. The stock has a 52-week high of $89.74 and its 52-week low is $61.45.

In the past 3 years, the stock has given returns of 16.12%. GILD has a 50-day moving Avg. and 200-day moving Avg. of $77.36 and $81.23, respectively.

Quarter performance – GILD revenues increased by 5% and 1% to $6.6bn and $13bn for the three and six months ended June 30, 2023, respectively, compared to the same periods in 2022, primarily due to higher product sales in HIV and Oncology, partially offset by lower sales of Veklury.

Company Guidance for FY23 – GILD expects total product sales between $26.3bn and $26.7bn, compared to $26bn and $26.5bn previously.

Total product sales, excluding Veklury, between $24.6bn and $25bn, compared to $24bn and $24.5bn previously. Total Veklury sales of ~$1.7bn, compared to approximately $2bn previously.

Diluted earnings per share between $4.50 and $4.85, compared to $4.75 and $5.15 previously. Non-GAAP diluted earnings per share between $6.45 and $6.8, compared to $6.60 and $7.00 previously.

Highlights

The company is showcasing its leadership in viral liver diseases, exemplifying its commitment to this critical healthcare area. The company is actively engaged in research, development, and treatments related to viral liver diseases. Their dedication to addressing the challenges posed by these diseases highlights their leadership role in improving patient outcomes and advancing healthcare solutions in the field of viral liver diseases.

This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– Drug Sales (Actual)
– Drug Sales (Forecasted)
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Developments
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages: 40

To download the previous quarter’s equity/ stock report CLICK HERE

To Download other equity/ stock reports CLICK HERE

Follow our LinkedIn page for more updates.